SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Spaak J) "

Sökning: WFRF:(Spaak J)

  • Resultat 1-10 av 84
  • [1]234567...9Nästa
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
1.
  •  
2.
  •  
3.
  •  
4.
  • Völz, Sebastian, 1980-, et al. (författare)
  • Renal sympathetic denervation in Sweden: a report from the Swedish registry for renal denervation.
  • 2018
  • Ingår i: Journal of hypertension. - 1473-5598. ; 36:1, s. 151-158
  • Tidskriftsartikel (refereegranskat)abstract
    • Renal denervation (RDN) is a catheter-based intervention to treat patients with resistant hypertension. The biological effects of RDN are not fully understood, and randomized controlled trials have generated conflicting evidence. This report presents data from the Swedish Registry for Renal Denervation, an investigator-driven nationwide registry.To assess the safety and efficacy of RDN on patients with resistant hypertension in a real-world clinical setting.This nationwide database contains patient characteristics, procedural details, and follow-up data on all RDN procedures performed in Sweden. Consecutive procedures between 2011 and 2015 were included.The data analysis consists of 252 patients (mean age 61 ± 10 years, 38% women; mean 4.5 ± 1.5 antihypertensive drugs). Office SBP and DBP and 24-h ambulatory blood pressure (BP) decreased 6 months after RDN (176 ± 23/97 ± 17 to 161 ± 26/91 ± 16 mmHg, both P < 0.001; and 155 ± 17/89 ± 14 to 147 ± 18/82 ± 12 mmHg, both P < 0.001). Significant office and ambulatory BP reductions persisted throughout the observation period of 36 months. Major procedure-related vascular complications occurred in four patients. Renal function and number of antihypertensive drugs were unchanged during follow-up.In this complete national cohort, RDN was associated with a sustained reduction in office and ambulatory BP in patients with resistant hypertension. The procedure proved to be feasible and associated with a low-complication rate, including long-term adverse events.
  •  
5.
  • Batra, Gorav, et al. (författare)
  • Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers Are Associated With Improved Outcome but do Not Prevent New-Onset Atrial Fibrillation After Acute Myocardial Infarction
  • 2017
  • Ingår i: Journal of the American Heart Association. - Wiley-Blackwell. - 2047-9980. ; 6:3
  • Tidskriftsartikel (refereegranskat)abstract
    • Background-Treatment with renin-angiotensin system (RAS) inhibitors might restrain the structural/electrical remodeling associated with atrial fibrillation (AF). Limited evidence exists regarding the potential benefits of RAS inhibition post-acute myocardial infarction (AMI) in patients with AF. This study sought to assess the association between RAS inhibition and all-cause mortality and new-onset AF in patients with/without congestive heart failure (CHF) post-AMI. Methods and Results--Patients hospitalized for AMI between 2006 and 2012 were identified in Swedish registries. Patients were stratified in 4 subgroups; patients with CHF and AF (n=11 489); patients with CHF without AF (n=31 676); patients with AF without CHF (n=10 066); and patients without both CHF and AF (n=59 417). Patients exposed to RAS inhibition were compared to nontreated. Three-year risk of all-cause mortality and new-onset AF was assessed using adjusted Cox regression analyses. At discharge, 83 291 (73.9%) patients received RAS inhibition. RAS inhibition was associated with lower 3-year risk of all-cause mortality in CHF patients with AF, adjusted hazard ratio (HR) with 95% CI 0.75 (0.70-0.81), CHF patients without AF, HR 0.65 (0.60-0.69), AF patients without CHF, HR 0.82 (0.75-0.90), and in patients without CHF and AF, HR 0.76 (0.72-0.81), respectively. RAS inhibition was not associated with lower 3-year risk of new-onset AF in patients without AF but with/without CHF; HR 0.96 (0.84-1.10) and 1.12 (1.02-1.22), respectively. Conclusions--RAS inhibition post-AMI was associated with lower risk of all-cause mortality. In patients with/without CHF, RAS inhibition was not associated with lower incidence of new-onset AF.
6.
  •  
7.
  •  
8.
  •  
9.
  • Szummer, K, et al. (författare)
  • Association between the use of fondaparinux vs low-molecular-weight heparin and clinical outcomes in patients with non-ST-segment elevation myocardial infarction
  • 2015
  • Ingår i: Journal of the American Medical Association (JAMA). - 0098-7484 .- 1538-3598. ; 313:7, s. 707-716
  • Tidskriftsartikel (refereegranskat)abstract
    • <p>IMPORTANCE: Fondaparinux was associated with reduced major bleeding events and improved survival compared with low-molecular-weight heparin (LMWH) in a large randomized clinical trial involving patients with non-ST-segment elevation myocardial infarction (NSTEMI). Large-scale experience of the use of fondaparinux vs LMWH in a nontrial setting is lacking.</p><p>OBJECTIVE: To study the association between the use of fondaparinux vs LMWH and outcomes in patients with NSTEMI in Sweden.</p><p>DESIGN, SETTING, AND PATIENTS: Prospective multicenter cohort study from the Swedish Web-System for Enhancement and Development of Evidence-Based Care in Heart Disease Evaluated According to Recommended Therapies registry involving 40,616 consecutive patients with NSTEMI who received fondaparinux or LMWH between September 1, 2006, through June 30, 2010, with the last follow-up on December 31, 2010.</p><p>EXPOSURES: In-hospital treatment with fondaparinux or LMWH during the hospital stay.</p><p>MAIN OUTCOMES AND MEASURES: In-hospital severe bleeding events and death and 30- and 180-day death, MI, stroke, and major bleeding events. Logistic regression models adjusted for calendar time, admitting hospital, baseline characteristics, and in-hospital revascularization.</p><p>RESULTS: In total, 14,791 patients (36.4%) were treated with fondaparinux and 25,825 (63.6%) with LMWH. One hundred sixty-five patients (1.1%) in the fondaparinux group vs 461 patients (1.8%) in the LMWH group experienced in-hospital bleeding events (adjusted odds ratio [OR], 0.54; 95% CI, 0.42-0.70). A total of 394 patients (2.7%) in the fondaparinux group died while in the hospital vs 1022 (4.0%) in the LMWH group (adjusted OR, 0.75; 95% CI, 0.63-0.89). The differences in major bleeding events and mortality between the 2 treatments were similar at 30 and 180 days. There were no significant differences in the number of recurrent MI and stroke events at 30 or 180 days among the 2 treatment groups.</p><p>CONCLUSIONS AND RELEVANCE: In routine clinical care of patients with NSTEMI, fondaparinux was associated with lower odds than LMWH of major bleeding events and death both in-hospital and up to 180 days afterward.</p>
  •  
10.
  • Edfors, R., et al. (författare)
  • Use of proteomics to identify biomarkers associated with chronic kidney disease and long-term outcomes in patients with myocardial infarction
  • ????
  • Ingår i: Journal of Internal Medicine. - Wiley-Blackwell Publishing Ltd. - 0954-6820.
  • Tidskriftsartikel (refereegranskat)abstract
    • Background: Patients with chronic kidney disease (CKD) have poor outcomes following myocardial infarction (MI). We performed an untargeted examination of 175 biomarkers to identify those with the strongest association with CKD and to examine the association of those biomarkers with long-term outcomes. Methods: A total of 175 different biomarkers from MI patients enrolled in the Swedish Web-System for Enhancement and Development of Evidence-Based Care in Heart Disease Evaluated According to Recommended Therapies (SWEDEHEART) registry were analysed either by a multiple reaction monitoring mass spectrometry assay or by a multiplex assay (proximity extension assay). Random forests statistical models were used to assess the predictor importance of biomarkers, CKD and outcomes. Results: A total of 1098 MI patients with a median estimated glomerular filtration rate of 85 mL min−1/1.73 m2 were followed for a median of 3.2 years. The random forests analyses, without and with adjustment for differences in demography, comorbidities and severity of disease, identified six biomarkers (adrenomedullin, TNF receptor-1, adipocyte fatty acid-binding protein-4, TNF-related apoptosis-inducing ligand receptor 2, growth differentiation factor-15 and TNF receptor-2) to be strongly associated with CKD. All six biomarkers were also amongst the 15 strongest predictors for death, and four of them were amongst the strongest predictors of subsequent MI and heart failure hospitalization. Conclusion: In patients with MI, a proteomic approach could identify six biomarkers that best predicted CKD. These biomarkers were also amongst the most important predictors of long-term outcomes. Thus, these biomarkers indicate underlying mechanisms that may contribute to the poor prognosis seen in patients with MI and CKD.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 1-10 av 84
  • [1]234567...9Nästa
Åtkomst
fritt online (8)
Typ av publikation
tidskriftsartikel (79)
konferensbidrag (4)
forskningsöversikt (1)
Typ av innehåll
refereegranskat (76)
övrigt vetenskapligt (9)
Författare/redaktör
Spaak, J, (74)
Jernberg, T, (29)
Szummer, K., (19)
Evans, M. (18)
Carrero, JJ, (13)
Linnarsson, D, (13)
visa fler...
Hofman-Bang, C (11)
Jacobson, SH, (10)
Spaak, Jonas, (10)
Tornvall, P, (9)
Kahan, T, (8)
Lindhagen, Lars, (8)
Lindhagen, L (8)
Daniel, M., (7)
Norberg-Spaak, Lena, (7)
Agewall, S, (7)
Henareh, L, (7)
Collste, O, (7)
Andell, P (7)
James, S., (6)
Sorensson, P, (6)
Malmqvist, K, (6)
Frick, M, (6)
Ekenback, C, (6)
Jernberg, Tomas, (6)
Lagerqvist, B (6)
Fåhraeus, Robin, (6)
Coates, Philip J (6)
Nylander, Karin, (6)
Caidahl, K (5)
Boldrup, Linda, (5)
Erlinge, D (5)
Persson, H (4)
James, Stefan, (4)
Caidahl, Kenneth, 19 ... (4)
Oldgren, Jonas, (4)
Schenck-Gustafsson, ... (4)
Szummer, Karolina, (4)
Wilms, Torben, (4)
Sgaramella, Nicola, (4)
Evans, Marie (4)
Sundin, O (3)
Stenvinkel, P, (3)
Jorneskog, G, (3)
Carrero, J. J. (3)
Lindahl, B (3)
Andell, Pontus (3)
Varenhorst, C (3)
Carrero, Juan-Jesus, (3)
Berglund, F (3)
visa färre...
Lärosäte
Karolinska Institutet (62)
Lunds universitet (9)
Göteborgs universitet (7)
Umeå universitet (6)
Kungliga Tekniska Högskolan (6)
Uppsala universitet (6)
visa fler...
Linköpings universitet (1)
Mittuniversitetet (1)
visa färre...
Språk
Engelska (82)
Svenska (1)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (34)
Samhällsvetenskap (1)

År

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy